Taiwan Main Orthopaedic Biotechnology Co., Ltd.

SURGLASSES Inc. (Taiwan Main Orthopaedic Biotechnology Co., Ltd.) is a medical technology manufacturer specializing in augmented reality (AR) surgical guidance systems for orthopedic and neurosurgery applications. The company develops computer-assisted surgical navigation platforms designed to reduce X-ray radiation exposure, improve surgical precision, and enable minimally invasive procedures. Core product lines include the Caduceus S AR Navigation System (FDA 510(k) cleared in December 2022), a spine 3D computer surgery navigation system, and surgical planning software. The company also manufactures medical education platforms, including the Asclepius Virtual Dissection Table (available in multiple sizes for institutional use) and the Asclepius AI Table, described as the world's first AI-powered anatomy table featuring integrated modules for anatomy, radiology, histopathology atlas, and CT rendering. The Asclepius platform supports online examination and anatomy app functionality for medical schools and training institutions. SURGLASSES holds FDA 510(k) clearance and serves hospitals, physicians, and patients across North America and Asia-Pacific markets. The company reports completion of the first AR surgery procedure in the United States (April 2023). Operations include manufacturing and distribution facilities in Taiwan and the United States, with focus on reducing surgical time, improving outcomes, and lowering procedural costs through advanced visualization and navigation technologies.